Boehringer Ingelheim

Boehringer Ingelheim’s oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through our own scientific innovation and partnerships, we are focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals. Our oncology pipeline is robust and transformative, with contributions from both our in-house research and development programmes as well as from academic and industry partnerships. Our goal is to become a leader in the field of lung cancer, having launched two products for the treatment of non-small cell lung cancer (NSCLC) globally.